Sep 22, 2026 · 6 min
Alibaba’s AI push meets rallies in apparel and biotech
Alibaba and ON Rise; Viking Therapeutics Surges
The episode shows how technology investment, consumer-brand expansion, and drug-development data are moving distinct parts of the market.
- 1Alibaba’s new AI chip and larger-model plans underscore its ambition to expand data-center capacity.
- 2On Holding’s expected high-teens sales growth reflects expansion beyond running into golf and football.
- 3Viking Therapeutics surged after data suggested less frequent dosing could preserve most weight loss after GLP-1 treatment.
Don't miss
Viking Therapeutics’ sharp premarket gain follows data suggesting less frequent dosing could preserve most weight loss after GLP-1 treatment.
The brief
Alibaba shares rose after the company unveiled a new AI chip, outlined larger-model plans, and signaled ambitions to expand data-center capacity.
The discussion places Alibaba’s technology in a broader U.S.-China context, while briefly examining the growing use of “agentic AI” in consumer products.
On Holding gained on expectations for high-teens sales growth as the sportswear company expands into golf and football; its ownership includes Roger Federer.
Viking Therapeutics surged after results suggested its experimental obesity drug could maintain most weight loss with less frequent dosing after GLP-1 treatment.
Together, the moves show investors responding to different kinds of evidence: infrastructure plans, growth expectations, and clinical data.
What was said on this episode
4 statements · 4 positive
On Holding expects sales growth in the high teens over the next few years.
“It expects sales growth in the high teens over the next few years.”
Listen at 2:10
On Holding is trying to take market share from Adidas and Nike.
“take market share away from Adidas or Adidas in Germany and Nike”
Listen at 2:17
Viking Therapeutics’ drug produced 22% weight loss over 33 weeks in a maintenance study.
“this drug led to a 22% weight loss over 33 weeks in what they call a maintenance study”
Listen at 3:17
Viking Therapeutics’ drug could compete with Eli Lilly and Novo Nordisk.
“it could be a contender to Eli Lilly and Novo Nordisk”
Listen at 3:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Nvidia Corporation
Xi Jinping
Donald John TrumpListen to the full episode and explore every guest, topic, and moment on PodLume.